8:50 am Chair’s Opening Remarks
Applications of 3D Tissue Models to Support ADME & DMPK Studies
9:00 am Validating Skin-Based Complex In Vitro Models to Empower ADME & DMPK Predictions
Synopsis
- Explaining how CIVM provide a more physiologically relevant environment for studying PK, bioavailability and more
- Spotlighting strategies to ensure accurate recapitulation of the tissue microenvironment by using patient tissues
- Linking in vitro data with in vivo data to assess for correlations and empower formulation decision-making
9:30 am Establishing Reproducible Neuromuscular-on-a-chip Models to Empower Efficacy Predictions
Synopsis
- Showcasing the utilization of neuromuscular models to assess a spectrum of disorders including complement mediated, myotonic dystrophy, or immune-related responses
- Uncovering lessons learned from employing a CIVM to assess for pharmacology and efficacy studies
- Discussing how the efficacy assessments in neuromuscular models contribute to the optimization of candidate treatments, paving the way for enhanced interventions in the field
10:00 am Developing, Validating & Deploying in Vitro Models of the Central Nervous System to Inform Drug Development
Synopsis
- Investigating the degree to which different in vitro models recapitulate the human and mouse CNS
- Discussing how these models, paired with various assays, may predict drug-induced neurotoxicity
- Presenting data suggesting that the right combination of model and assay can reveal unique insights into on- and off-target toxicity
10:30 am Morning Break & Networking Coffee
Uncovering Optimized Strategies to Boost Toxicity Predictability Power Using Model Data
11:30 am Spotlighting Lessons Learned from Validating & Implementing Organoids to De-Risk Oncology Therapeutic Development
Synopsis
- Discussing the need to build robust protocols to enhance model reproducibility and empower their validation
- Employing techniques to characterize organoid and ensure reproducibility and translatability for safety studies
- Assessing the applications of organoids for safety considerations to de-risk therapeutic candidates before moving to patients
12:00 pm Empowering Oncology Drug Safety: Leveraging Reproducible Organ-on-a-Chip Models for Hazard Identification
Synopsis
- Discussing the limitations of current models for assessing immunotoxicity of cell engagers and cell therapies
- The ability of MPS model to mimic human physiological conditions, including cell-cell interactions and microenvironment dynamics, allows for more accurate predictions of drug responses
- Case study: Assessing on-target off-tumor toxicity for T-cell engagers and cell therapy
12:30 pm Lunch Break
Exploring the Future of Modeling & Spotlighting Newer Tools to Empower Drug Discovery
1:30 pm Fireside Chat: Assessing the Future of 3D Tissue Modeling
Synopsis
- Discussing the exciting model developments that have recently gained traction
- Spotlighting the analysis tools like spatial biology to empower model validation
2:15 pm Applying Back Translation to Validate Complex In Vitro Models
Synopsis
- Exploring optimized techniques to model lung pathobiology to develop a lung-in-a-dish model
- Addressing the need for back translation of clinical compounds using emerging models to empower their validation
- Spotlighting strategies to implement machine learning to empower compound screening and analysis
2:45 pm Harnessing Bioconvergence Including Validated MPS Data to Help Transform Drug Discovery & Development While Reducing Reliance on Animal Testing
Synopsis
- Utilizing bioconvergence to develop standardized methods for characterizing microphysiological systems, ensuring consistency and reliability across studies
- Leveraging bioconvergence to empower prediction modeling in drug discovery
- Collaborating with different functions to make the best out of the data outputs from this